Last updated on February 2018

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors


Brief description of study

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors or CTCL, and in combination with durvalumab and/or palliative radiation in subjects with solid tumors.

Detailed Study Description

This is a multicenter, unblinded study to evaluate the TLR 7/8 agonist MEDI9197 delivered by IT injection to subjects with solid tumors or CTCL, and in combination with durvalumab and/or palliative radiation in subjects with solid tumors. The study uses a 3 + 3 dose escalation design to evaluate a range of doses

Clinical Study Identifier: NCT02556463

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
San Francisco, CA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Aurora, CO United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Tampa, FL United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Minneapolis, MN United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
New York, NY United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Chapel Hill, NC United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Houston, TX United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Saint Louis, MO United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Philadelphia, PA United States
  Connect »